# A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

> clinical trial · VERIFIED · 2026-08-21

Status: RECRUITING · Sponsor: Merck Sharp & Dohme LLC · Condition: Prostate Cancer

- Company: Merck Sharp & Dohme LLC
- Sector: oncology
- Primary source: https://clinicaltrials.gov/study/NCT06925737

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.